NEOADJUVANT VIDUTOLIMOD (VIDU) AND NIVOLUMAB (NIVO) RESULTS IN MPR AND IMMUNE ACTIVATION IN HIGH-RISK RESECTABLE MELANOMA (MEL): FINAL PHASE II CLINICAL TRIAL RESULTSJOURNAL FOR IMMUNOTHERAPY OF CANCERIF10.62022-12-083OA
FINAL ANALYSIS: PHASE 1B STUDY INVESTIGATING INTRATUMORAL INJECTION OF TOLL-LIKE RECEPTOR 9 AGONIST VIDUTOLIMOD ± PEMBROLIZUMAB IN PATIENTS WITH PD-1 BLOCKADE-REFRACTORY MELANOMAJOURNAL FOR IMMUNOTHERAPY OF CANCERIF10.62021-11-106OA
未登录.png){kind=icon}
未登录
